Siegfried Holding AG

Swiss Stock Exchange SFZN.SW

Siegfried Holding AG Capital Expenditure for the year ending December 31, 2023: USD -162.83 M

Siegfried Holding AG Capital Expenditure is USD -162.83 M for the year ending December 31, 2023, a -30.70% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Siegfried Holding AG Capital Expenditure for the year ending December 31, 2022 was USD -124.59 M, a -0.23% change year over year.
Siegfried Holding AG Capital Expenditure for the year ending December 31, 2021 was USD -124.29 M, a -59.16% change year over year.
Siegfried Holding AG Capital Expenditure for the year ending December 31, 2020 was USD -78.10 M, a -22.22% change year over year.
Siegfried Holding AG Capital Expenditure for the year ending December 31, 2019 was USD -63.90 M, a -7.12% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Swiss Stock Exchange: SFZN.SW

Siegfried Holding AG

CEO	Mr. Marcel Imwinkelried
IPO Date	April 14, 1995
Location	Switzerland
Headquarters	Untere Bruehlstrasse 4
Employees	3,797
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Chemicals & Advanced Materials Clinical Trials Cosmetics Personal Care Plastics

Description

Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral dosage forms, and sterile and aseptic filling injectables, ophthalmics, and inhalative products. It offers contract development and manufacturing services, including pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale up and clinical trial material production. In addition, the company provides APIs and controlled substances focusing on anesthetics, pain treatment applications, and central nervous and respiratory diseases. Further, it licenses oral solid and sterile products; assembles registration dossiers; and offers a common technical document for various products. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.

Key trends

Past 5 years